Assessing anaphylactic risk? Consider mast cell clonality
- 1 March 2009
- journal article
- editorial
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 123 (3) , 687-688
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- New concepts in chronic urticariaCurrent Opinion in Immunology, 2008
- Understanding the mechanisms of anaphylaxisCurrent Opinion in Allergy and Clinical Immunology, 2008
- Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxisJournal of Allergy and Clinical Immunology, 2008
- Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patientsAllergy, 2008
- Concurrent Inhibition of Kit- and FcϵRI-Mediated Signaling: Coordinated Suppression of Mast Cell ActivationThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Kit- and FcɛRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cellsCellular Signalling, 2008
- Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxisBlood, 2007
- Risk assessment in anaphylaxis: Current and future approachesJournal of Allergy and Clinical Immunology, 2007
- Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response CriteriaEuropean Journal of Clinical Investigation, 2007
- The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis.Journal of Clinical Investigation, 1995